SCHEMBL2108172

SCHEMBL2108172

CN(CCCN)Cc1ccccc1

nearest known ligand 0.78

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CARM1 Q86X55 1/20 0.78
PRMT6 Q96LA8 1/20 0.78
PRMT8 Q9NR22 1/20 0.78
SIGMAR1 Q99720 3/20 0.65
MAOB P27338 4/20 0.53
MAOA P21397 1/20 0.53
LMNA P02545 1/20 0.53
AOC3 Q16853 1/20 0.52
ALDH1A1 P00352 2/20 0.50
ACHE P22303 2/20 0.50
TSHR P16473 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
KDM4E B2RXH2 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
TMEM97 Q5BJF2 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL18730544 0.98 CARM1 (0.75) CARM1PRMT6PRMT8SIGMAR1MAOB
SCHEMBL4604745 0.94 CARM1 (0.75) CARM1PRMT6PRMT8SIGMAR1MAOB
SCHEMBL25688953 0.92 CARM1 (0.72) CARM1PRMT6PRMT8SIGMAR1MAOB
SCHEMBL8342032 0.92 CARM1 (0.72) CARM1PRMT6PRMT8SIGMAR1MAOB
Hydrochloric Acid SCHEMBL9373710 0.92 CARM1 (0.72) CARM1PRMT6PRMT8SIGMAR1MAOB
SCHEMBL1395704 0.88 CARM1 (1.00) CARM1PRMT6PRMT8SIGMAR1MAOB
SCHEMBL1088446 0.87 SIGMAR1 (0.74) CARM1PRMT6PRMT8SIGMAR1MAOB
Hydrochloric Acid SCHEMBL17372655 0.86 CARM1 (0.96) CARM1PRMT6PRMT8SIGMAR1MAOB
Hydrochloric Acid SCHEMBL1087168 0.85 SIGMAR1 (0.71) CARM1PRMT6PRMT8SIGMAR1MAOB
SCHEMBL29733117 0.85 SIGMAR1 (0.85) CARM1PRMT6PRMT8SIGMAR1MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9328093-B2 Selective inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications HYBRIGENICS SA (FR) 2016-05-03 US claimed
US-20150072973-A1 NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2015-03-12 US claimed
CN-101045759-B Styrene or substituted styrene polymer type quaternary ammonium salt antistat or bacterial agent and preparation method thereof DINGLAN GREEN CHEMICAL INST CO LTD CHANGZHOU 2011-06-01 CN claimed
CN-101045759-A Styrene or substituted styrene polymer type quaternary ammonium salt antistat or bacterial agent and preparation method thereof DINGLAN GREEN CHEMICAL INST CO (CN) 2007-10-03 CN claimed
EP-0427765-B1 ALKOXY-4(1H)-PYRIDONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USE AS DRUGS GOEDECKE AG (DE) 2000-01-05 EP claimed
US-5185352-A Treating or preventing cardiovascular disorders GOEDECKE AKTIENGESELLSCHAFT (DE) 1993-02-09 US claimed
US-12378255-B2 Toll-like receptor antagonist compounds and methods of use DYNAVAX TECHNOLOGIES CORPORATION (US) 2025-08-05 US disclosed
US-20240182478-A1 TOLL-LIKE RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USE DYNAVAX TECHNOLOGIES CORPORATION 2024-06-06 US disclosed
CN-114651025-B Curable composition, cured product, fiber-reinforced composite material, molded article, and method for producing same DIC株式会社 2024-06-04 CN disclosed
US-20240101584-A1 TARGETED DELIVERY OF 1,2,4,5 TETRAOXANE COMPOUNDS AND THEIR USES Westlake University (CN) 2024-03-28 US disclosed
CN-117157281-A Targeted delivery of 1,2,4, 5-tetraoxacompounds and uses thereof 西湖大学 2023-12-01 CN disclosed
US-11827641-B2 Toll-like receptor antagonist compounds and methods of use DYNAVAX TECHNOLOGIES CORPORATION (US) 2023-11-28 US disclosed
US-11827641-B2 Toll-like receptor antagonist compounds and methods of use DYNAVAX TECHNOLOGIES CORPORATION (US) 2023-11-28 US disclosed
EP-0061673-B1 ISOQUINOLINESULFONYL DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF Asahi Kasei Kogyo Kabushiki Kaisha (JP) 1984-10-24 EP disclosed
US-4456757-A MUSCLE RELAXANTS, VASODILATORS, HYPOTENSIVE AGENTS ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 1984-06-26 US disclosed
EP-0061673-A1 Isoquinolinesulfonyl derivatives and process for the preparation thereof Asahi Kasei Kogyo Kabushiki Kaisha (JP) 1982-10-06 EP disclosed
EP-0014899-B1 PROCESS FOR THE PREPARATION OF CATIONIC ANTHRAQUINONE DYES BAYER AG (DE) 1981-10-21 EP disclosed
US-4296044-A AMINATION, QUATERNIZATION BAYER AKTIENGESELLSCHAFT (DE) 1981-10-20 US disclosed
EP-0014899-A1 Process for the preparation of cationic anthraquinone dyes BAYER AG (DE) 1980-09-03 EP disclosed
US-4091001-A Liquid coating compositions containing glycidyl ester-polyamine binders CHEMISCHE WERKE HUELS AKTIENGESELLSCHAFT (DT) 1978-05-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240182478-A1 TOLL-LIKE RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USE TLR7, TLR9, TLR1 CARM1 2881/4885PRMT6 4139/4885PRMT8 1856/4885
US-20240101584-A1 TARGETED DELIVERY OF 1,2,4,5 TETRAOXANE COMPOUNDS AND THEIR USES AIFM2, GPX1, GPX4 CARM1 1324/4885PRMT6 2107/4885PRMT8 2023/4885
US-11827641-B2 Toll-like receptor antagonist compounds and methods of use TLR7, TLR9, TLR1 CARM1 2881/4885PRMT6 4139/4885PRMT8 1856/4885
US-12378255-B2 Toll-like receptor antagonist compounds and methods of use TLR7, TLR9, TLR1 CARM1 2881/4885PRMT6 4139/4885PRMT8 1856/4885
US-20150072973-A1 NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS USP7, SENP7, PSMA7 CARM1 3263/4885PRMT6 1702/4885PRMT8 1190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.